Graham Kelly - Chief Executive Officer
BSc (Vet) (Hons, BVSc (Hons), PhD
Graham currently is part-time CEO while the Company is conducting the search for a full-time US-based CEO. Graham graduated with degrees in Science (1968) and Veterinary Science (1969) from The University of Sydney. After graduation he joined the newly-formed Department of Transplant Surgery in the Faculty of Medicine at The University of Sydney, gaining a Doctor of Philosophy (Medicine) in 1972. The subject of his PhD thesis was the manufacture and use of a novel drug for the treatment of tissue rejection in kidney transplant recipients, with that drug subsequently being commercialised and used globally in kidney transplantation. Graham was appointed Senior Research Fellow in Experimental Surgery at The University of Sydney, conducting active research in the areas of patient monitoring for tissue rejection and organ retrieval for transplantation. By the mid-1980s, the increased susceptibility of organ transplant recipients to malignant cancer eventually led Graham to focus on the cancer-causing mechanisms operating in organ transplant recipients.
In the early-1990s, Graham identified the compound idronoxil as a promising anti-cancer drug. Graham left academia and founded the company, Norvet Ltd, which listed on the ASX in 1994. That company subsequently changed its name to Novogen Ltd and listed on NASDAQ (1998). Graham was variously CEO, Executive Chairman and an Executive Director of Novogen, 1994-2006. He also was Executive Chairman of Marshall Edwards Inc (MEI) which listed on London's AIM exchange (2001) and NASDAQ (2003). MEI subsequently became MEI Pharma Inc. Graham resigned from his executive and Board positions at Novogen and MEI in 2006.
In 2012, Graham established a private biotechnology company, Macmaster Healthcare, which focused on developing a delivery technology to preserve the activity of idronoxil in the body. That technology eventually became known as the LIPROSE drug delivery technology.
Graham rejoined Novogen in late-2012, remaining as CEO and Executive Chairman until June 2015. In that time, he was responsible for the concepts and development of the drug candidates, Cantrixil and Trilexium, and the creation of a joint venture company with Yale University. After leaving Novogen in 2015, Graham transformed Macmaster Healthcare and the LIPROSE technology platform into Noxopharm Limited, which listed on the Australian Securities Exchange in August 2016.
Graham currently is Group CEO of Noxopharm Ltd, Asian subsidiary, Noxopharm Asia Pty Ltd, and US subsidiary, Nyrada Inc.